Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 3/20 | 0.48 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.47 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.47 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.47 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.47 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.43 |
| ▸ | CDC25B | P30305 | 6/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.42 |
| ▸ | GJB2 | P29033 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8907921 | 0.95 | SSTR1 (0.47) | TACR2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL6952287 | 0.94 | GJB2 (0.48) | TACR2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL8790682 | 0.92 | HTR1A (0.52) | TACR2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL8790678 | 0.92 | HTR1A (0.52) | TACR2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL6763788 | 0.90 | SSTR1 (0.52) | TACR2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL7078169 | 0.89 | TACR2 (0.49) | TACR2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL8907490 | 0.86 | GJB2 (0.43) | TACR2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL8630332 | 0.86 | GJB2 (0.43) | TACR2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL7148238 | 0.86 | SSTR1 (0.57) | TACR2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL5688919 | 0.85 | HTR1A (0.47) | TACR2SSTR1SSTR2SSTR4SSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3197907-B1 | VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE SEROTYPE 8 | MAX PLANCK GESELLSCHAFT (DE) | 2019-09-04 | — | — | EP | disclosed |
| US-10220083-B2 | Vaccines against Streptococcus pneumoniae serotype 8 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2019-03-05 | — | — | US | disclosed |
| US-20170239341-A1 | VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE SEROTYPE 8 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-08-24 | — | — | US | disclosed |
| EP-3197907-A1 | VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE SEROTYPE 8 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften (DE) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016046420-A1 | VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE SEROTYPE 8 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-03-31 | — | — | WO | disclosed |
| EP-3000820-A1 | Synthetic vaccines against Streptococcus pneumoniae serotype 8 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-03-30 | — | — | EP | disclosed |
| US-6723843-B2 | USE OF A 2-SUBSTITUTED-1,3-DIOXOCYCLOALKYL LINKER GROUP TO COUPLE SACCHARIDE GROUPS OF BOTH THE O-GLYCOSIDE AND N-GLYCOSIDE TYPE TO A POLYMER SUPPORT IN A SOLID PHASE SYSTHESIS PROCESS | ALCHEMIA PTY LTD (AU) | 2004-04-20 | — | — | US | disclosed |
| US-6573337-B1 | Dioxocyclohexane compound linker for solid-phase synthesis of oligosaccharides | ALCHEMIA PTY LTD (AU) | 2003-06-03 | — | — | US | disclosed |
| US-20030027925-A1 | Oligosaccharide synthesis | ALCHEMIA PTY LTD | 2003-02-06 | — | — | US | disclosed |
| EP-0923528-B1 | OLIGOSACCHARIDE SYNTHESIS | ALCHEMIA PTY LTD (AU) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10220083-B2 | Vaccines against Streptococcus pneumoniae serotype 8 | LGALS8, SIGLEC7, FUT5 | TACR2 3961/4885SSTR1 2106/4885SSTR2 2976/4885 |
| US-20170239341-A1 | VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE SEROTYPE 8 | LGALS8, SIGLEC7, FUT5 | TACR2 3961/4885SSTR1 2106/4885SSTR2 2976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.